HR Execs on the Move

Biogen Idec

www.biogenidec.com

 
We are a global biotechnology company, specializing in discovering, developing, and delivering innovative therapies for the treatment of neurodegenerative, non-malignant hematologic and autoimmune diseases to patients worldwide. As a company, we are focused on cutting-edge science and medicines that address unmet patient needs and change the course of these devastating diseases. Founded in 1978, we are the world`s oldest independent biotechnology company and take pride in being known for pioneering the development of leading multiple sclerosis therapies.    With approximately 7,000 employees worldwide, we are focused on better understanding the underlying biology of diseases so we can discover and deliver innovative treatments ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Anju Nagpal
 DIRECTOR - R&D FINANCE Profile
Jerald Novak
 Senior Director - Human Resources Profile
Amanda Sorrento
 Human Resources Director - Research and Development - Corporate Strategy - Corporate Development and Early Pipeline Programs Profile
Andrea Blake
 Director - Human Resources -Global Quality Profile
Kelly Clements
 Director - Employee Relations Profile

Similar Companies

Alexander G

Alexander G is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Controle Analytique Inc

Controle Analytique Inc is a Thetford Mines, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NaturalNano Inc

NaturalNano Inc is a Pittsford, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Elastrin Therapeutics

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice.

Onconova

Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. Onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.